The transcript for Amgen's second quarter 2016 earnings call presents a mixed but generally positive outlook for the company. Here are the key points that influence the short-term impact on the stock price:

1. **Strong Financial Performance**: Amgen reported a 6% year-over-year increase in revenues, with non-GAAP operating income growing 10% and non-GAAP EPS increasing 11%[4].
2. **Product Performance**: The company's growth products, such as Prolia, XGEVA, ENBREL, and others, continued to drive strong sales growth. However, there were challenges with legacy products like EPOGEN and NEUPOGEN due to competition and market shifts[4].
3. **Pipeline Progress**: Amgen highlighted significant advancements in its pipeline, including positive data for erenumab in migraine treatment, progress on Repatha and Kyprolis, and the submission of romosozumab for osteoporosis treatment[4].
4. **Guidance and Outlook**: The company increased its 2016 revenue and non-GAAP EPS guidance, indicating continued confidence in its strategy and execution[4].
5. **Biosimilars and Competition**: Amgen is actively developing biosimilars, with several products in advanced regulatory stages. However, the competitive landscape, especially in the multiple myeloma market with products like Darzalex, was noted[4].

Given these points, here are the implications for the stock:

- The strong financial performance, positive pipeline updates, and increased guidance are likely to be viewed positively by investors.
- However, the competitive pressures and challenges with legacy products might introduce some caution.

### Conclusion

The overall tone of the earnings call suggests that Amgen is executing well on its strategy, with strong financials and promising pipeline developments. Despite some competitive challenges, the stock is likely to see a positive impact in the short term.

### Rating
[1]